The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences Inc.’s Veklury (remdesivir), an antiviral drug for the treatment of patients with COVID19 requiring hospitalization, according to the company’s press release. Veklury stops replication of the SARS-CoV-2 virus that causes COVID-19
- Veklury is the first and only approved COVID-19 treatment in the U.S. and is widely available in hospitals across the country.
- Veklury is recommended for adults and pediatric patients of 12 years of age and above weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization.
- Veklury should only be administered in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
- Veklury is contraindicated in patients who are allergic to Veklury and any of its components.
Gilead Sciences stock is gaining on vaccine approval. GLD: NASDAQ is up 4.41%
